Table 1.

The response of primary and metastatic lesions to gefitinib in responders

Site	No. of patients	No. improved	No. of patients with target lesion	Average tumor shrinkage of target lesion (%, mean ± SD)
Primary lesion	27	27	21	46.5 ± 19.4
Metastatic lesion
Intrapulmonary	12	12	9	73.8 ± 30.6
Liver	4	4	3	47.3 ± 21.6
CNS	4	4	2	65.0 ± 21.2
Bone	8	0
Pleural effusion	6	5
Others	2	2

CNS, central nervous system